clinical_trials
STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study
Confidence88·multiple reportsImportance90NP-EVT-20261028-37C1112
Eli Lilly announced that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study.
Read the original at the primary source
STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study
Elaine Chen · 10/28/2026, 1:42:44 PM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse
Discussion
ChatsPulse · 0 threads
No discussion yet. Sign in and start the first thread —